ABSTRACT
Where a company chooses to apply quality by design and quality risk management (ICH Q9, Quality Risk Management), linked to an appropriate pharmaceutical quality system, then opportunities arise to enhance science-and riskbased regulatory approaches, which is the subject of this chapter.
